CY1116316T1 - Μεθοδοι και συνθεσεις που περιλαμβανουν υπερμοριακα μορφωματα - Google Patents

Μεθοδοι και συνθεσεις που περιλαμβανουν υπερμοριακα μορφωματα

Info

Publication number
CY1116316T1
CY1116316T1 CY20151100465T CY151100465T CY1116316T1 CY 1116316 T1 CY1116316 T1 CY 1116316T1 CY 20151100465 T CY20151100465 T CY 20151100465T CY 151100465 T CY151100465 T CY 151100465T CY 1116316 T1 CY1116316 T1 CY 1116316T1
Authority
CY
Cyprus
Prior art keywords
methods
present
compositions including
variety
antibodies
Prior art date
Application number
CY20151100465T
Other languages
Greek (el)
English (en)
Inventor
Claude Yves Nicolau
Ruth Greferath
David Hickman
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/783,975 external-priority patent/US20040242845A1/en
Priority claimed from US10/958,211 external-priority patent/US8663650B2/en
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of CY1116316T1 publication Critical patent/CY1116316T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20151100465T 2004-02-20 2015-05-25 Μεθοδοι και συνθεσεις που περιλαμβανουν υπερμοριακα μορφωματα CY1116316T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/783,975 US20040242845A1 (en) 2003-02-21 2004-02-20 Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
US10/958,211 US8663650B2 (en) 2003-02-21 2004-10-04 Methods and compositions comprising supramolecular constructs
EP12153152.9A EP2465533B1 (en) 2004-02-20 2005-02-22 Methods and compositions comprising supramolecular constructs

Publications (1)

Publication Number Publication Date
CY1116316T1 true CY1116316T1 (el) 2017-02-08

Family

ID=46395388

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100465T CY1116316T1 (el) 2004-02-20 2015-05-25 Μεθοδοι και συνθεσεις που περιλαμβανουν υπερμοριακα μορφωματα

Country Status (11)

Country Link
JP (1) JP4934433B2 (es)
KR (1) KR101277004B1 (es)
CY (1) CY1116316T1 (es)
DK (1) DK2465533T3 (es)
ES (2) ES2385226T3 (es)
HK (2) HK1130698A1 (es)
HR (1) HRP20150612T1 (es)
HU (1) HUE025186T2 (es)
PT (1) PT2465533E (es)
RS (1) RS54074B1 (es)
SI (1) SI2465533T1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010224824B2 (en) * 2009-03-18 2014-02-20 Ac Immune S.A. Method for therapeutic use
CN103189050B (zh) * 2010-10-26 2017-09-29 Ac免疫有限公司 包含通过疏水部分修饰的肽的基于脂质体的构建体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187335B1 (en) * 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
WO1999041279A2 (en) * 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
EP1259563B2 (en) * 1999-12-22 2016-08-10 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.

Also Published As

Publication number Publication date
PT2465533E (pt) 2015-06-24
HUE025186T2 (en) 2016-02-29
ES2385226T3 (es) 2012-07-19
DK2465533T3 (en) 2015-04-20
KR101277004B1 (ko) 2013-06-24
ES2385226T9 (es) 2013-10-10
HK1172260A1 (en) 2013-04-19
SI2465533T1 (sl) 2015-07-31
HRP20150612T1 (hr) 2015-07-03
JP4934433B2 (ja) 2012-05-16
JP2007527870A (ja) 2007-10-04
HK1130698A1 (en) 2010-01-08
KR20120097546A (ko) 2012-09-04
RS54074B1 (en) 2015-10-30
ES2539262T3 (es) 2015-06-29

Similar Documents

Publication Publication Date Title
ATE552848T1 (de) Verfahren und zusammensetzungen mit supramolekularen konstrukten
CY1115014T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΕΙΔΙΚΑ ΓΙΑ Αβ1-42 ΜΕ ΘΕΡΑΠΕΥΤΙΚΕΣ ΙΔΙΟΤΗΤΕΣ
CY1119792T1 (el) Βασισμενη σε πρωτεϊνες θεραπεια και διαγνωση tau-διαμεσολαβουμενης παθολογιας σε νοσο του alzheimer
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
EA200601671A1 (ru) Идентификация собственных и чужеродных антигенов, вовлечённых в аутоиммунные заболевания
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
ATE510851T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atherosklerose
CY1117643T1 (el) Συνθεσεις νεϊσσεριακου εμβολιου που περιλαμβανουν συνδυασμο αντιγονων
AT500379B8 (de) Tau-proteine
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1110634T1 (el) Μεθοδοι προληψης και θεραπειας της νοσου του αλτσχαϊμερ (ad)
EA200700136A1 (ru) Анти-cd154-антитела
CY1115316T1 (el) Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων
AU2003270643A8 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
EP2403871A4 (en) SPECIFIC ANTIBODIES AND EPITOPES OF A PRION PROTEIN
CY1116316T1 (el) Μεθοδοι και συνθεσεις που περιλαμβανουν υπερμοριακα μορφωματα
ATE530565T1 (de) Impfstoff zur prävention und behandlung von progressiver atrophischer rhinitis in schweinen
ATE450272T1 (de) Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
CY1105947T1 (el) Νουκλεϊνικα οξεα και πρωτεϊνες του γονιδιου mhp3 του mycoplasma hyopneumoniae και χρησεις αυτων
MX2022011199A (es) Peptidos ciclicos.
DK1019085T3 (da) Ikke-anafylaktiske former for allergener og deres anvendelse